ETRASIMOD IN THE TREATMENT OF ULCERATIVE COLITIS: EFFICACY, SAFETY, AND ITS ROLE IN THERAPY - REVIEW
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease of the large intestine, often associated with significant impacts on patients' quality of life and public health systems. Traditional treatments, such as aminosalicylates, are not always effective, especially in moderate to severe cases. Etrasimod, a novel oral selective modulator of sphingosine-1-phosphate (S1P) receptors, offers an innovative therapeutic approach by regulating immune cell migration and reducing intestinal inflammation. This review explores the efficacy, safety, and potential role of Etrasimod in the treatment of UC. Recent clinical trials have demonstrated its significant effectiveness in both the induction and maintenance of remission in patients with moderately to severely active UC. The drug also shows a favorable safety and tolerability profile. These findings position Etrasimod as a promising alternative for patients who do not respond to standard therapies. As research progresses, Etrasimod may represent a step forward in the development of more targeted, disease-modifying treatments for ulcerative colitis.
Aim of the study: This review investigates Etrasimod’s role in ulcerative colitis treatment, in particular focusing on its mechanism of action, clinical efficacy, and safety. It seeks to determine whether it could serve as an alternative for patients resistant to conventional treatments.
Methodology: A literature review was conducted using PubMed, Google Scholar, and clinical trial registries.
Summary: Ulcerative colitis treatment remains challenging, with many patients experiencing limited benefits from existing therapies. Etrasimod, a selective modulator targeting S1P receptors, has demonstrated efficacy in induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. Findings from clinical trials, particularly ELEVATE UC 12, 40 JAPAN and 52, suggest its potential in ulcerative colitis treatment. Further long-term studies are needed to confirm its benefits.
References
Adams, S. M., Close, E. D., & Shreenath, A. P. (2022). Ulcerative Colitis: Rapid Evidence Review. American Family Physician, 105(4), 406–411.
Boal Carvalho, P., & Cotter, J. (2017). Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs, 77(2), 159–173. https://doi.org/10.1007/s40265-016-0676-y
da Silva, B. C., Lyra, A. C., Rocha, R., & Santana, G. O. (2014). Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World Journal of Gastroenterology : WJG, 20(28), 9458–9467. https://doi.org/10.3748/wjg.v20.i28.9458
de Campos Silva, E. F., Baima, J. P., de Barros, J. R., Tanni, S. E., Schreck, T., Saad-Hossne, R., & Sassaki, L. Y. (2020). Risk factors for ulcerative colitis-associated colorectal cancer. Medicine, 99(32), e21686. https://doi.org/10.1097/MD.0000000000021686
Etrasimod for moderate to severe ulcerative colitis. (n.d.). Australian Prescriber, 48(1), 25–26. https://doi.org/10.18773/austprescr.2025.004
Faggiani, I., Fanizza, J., D’Amico, F., Allocca, M., Zilli, A., Parigi, T. L., Barchi, A., Danese, S., & Furfaro, F. (2024). Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment. Biomedicines, 12(8), 1839. https://doi.org/10.3390/biomedicines12081839
Feuerstein, J. D., Isaacs, K. L., Schneider, Y., Siddique, S. M., Falck-Ytter, Y., & Singh, S. (2020). American Gastroenterological Association Institute Clinical Guideline on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology, 158(5), 1450–1461. https://doi.org/10.1053/j.gastro.2020.01.006
Gajendran, M., Loganathan, P., Jimenez, G., Catinella, A. P., Ng, N., Umapathy, C., Ziade, N., & Hashash, J. G. (2019). A comprehensive review and update on ulcerative colitis,. Disease-a-Month, 65(12), 100851. https://doi.org/10.1016/j.disamonth.2019.02.004
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., Harwood, C., Juillerat, P., Lobaton, T., Müller-Ladner, U., Noor, N., Pellino, G., Savarino, E., Schramm, C., Soriano, A., … Kucharzik, T. (2024). ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 18(1), 1–37. https://doi.org/10.1093/ecco-jcc/jjad108
Hlavaty, T., Toth, J., Koller, T., Krajcovicova, A., Oravcova, S., Zelinkova, Z., & Huorka, M. (2013). Smoking, breastfeeding, physical inactivity, contact with animals, and size of the family influence the risk of inflammatory bowel disease: A Slovak case–control study. United European Gastroenterology Journal, 1(2), 109–119. https://doi.org/10.1177/2050640613478011
Kucharzik, T., Koletzko, S., Kannengiesser, K., & Dignass, A. (2020). Ulcerative Colitis—Diagnostic and Therapeutic Algorithms. Deutsches Ärzteblatt International, 117(33–34), 564–574. https://doi.org/10.3238/arztebl.2020.0564
Liang, Y., Li, Y., Lee, C., Yu, Z., Chen, C., & Liang, C. (2024). Ulcerative colitis: Molecular insights and intervention therapy. Molecular Biomedicine, 5, 42. https://doi.org/10.1186/s43556-024-00207-w
Nakase, H., Sato, N., Mizuno, N., & Ikawa, Y. (2022). The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmunity Reviews, 21(3), 103017. https://doi.org/10.1016/j.autrev.2021.103017
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012). Ulcerative colitis. Lancet (London, England), 380(9853), 1606–1619. https://doi.org/10.1016/S0140-6736(12)60150-0
Porter, R. J., Kalla, R., & Ho, G.-T. (2020). Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Research, 9, F1000 Faculty Rev-294. https://doi.org/10.12688/f1000research.20805.1
Sandborn, W. J., Peyrin-Biroulet, L., Zhang, J., Chiorean, M., Vermeire, S., Lee, S. D., Kühbacher, T., Yacyshyn, B., Cabell, C. H., Naik, S. U., Klassen, P., & Panés, J. (2020). Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology, 158(3), 550–561. https://doi.org/10.1053/j.gastro.2019.10.035
Sandborn, W. J., Vermeire, S., Peyrin-Biroulet, L., Dubinsky, M. C., Panes, J., Yarur, A., Ritter, T., Baert, F., Schreiber, S., Sloan, S., Cataldi, F., Shan, K., Rabbat, C. J., Chiorean, M., Wolf, D. C., Sands, B. E., D’Haens, G., Danese, S., Goetsch, M., & Feagan, B. G. (2023). Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet, 401(10383), 1159–1171. https://doi.org/10.1016/S0140-6736(23)00061-2
Segal, J. P., LeBlanc, J.-F., & Hart, A. L. (2021). Ulcerative colitis: An update. Clinical Medicine, 21(2), 135–139. https://doi.org/10.7861/clinmed.2021-0080
Takeuchi, K., Hisamatsu, T., Nakase, H., Matsuoka, K., Keating, M., Yuasa, H., Oe, M., Arai, S., Mazur, R., & Hibi, T. (2025). Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials. Digestion, 106(3), 167–175. https://doi.org/10.1159/000541383
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017). Ulcerative colitis. Lancet (London, England), 389(10080), 1756–1770. https://doi.org/10.1016/S0140-6736(16)32126-2
Vermeire, S., Sands, B. E., Peyrin-Biroulet, L., D’Haens, G. R., Panés, J., Yarur, A. J., Wolf, D. C., Ritter, T., Schreiber, S., Woolcott, J. C., Modesto, I., Keating, M., Shan, K., Wu, J., Chiorean, M. V., Baert, F., Dubinsky, M. C., Goetsch, M., Danese, S., & Feagan, B. G. (2024). Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal of Crohn’s & Colitis, 18(11), 1780–1794. https://doi.org/10.1093/ecco-jcc/jjae079
Views:
464
Downloads:
246
Copyright (c) 2025 Patrycja Kardasz, Aleksandra Piech, Martyna Grodzińska, Tomasz Ufniarski, Maria Ufniarska, Karol Poplicha, Justyna Moszkowicz, Piotr Sobkiewicz, Karolina Pasierb, Bartłomiej Siuzdak, Marta Jutrzenka, Patrycja Ucieklak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
